Perceptive Discovery, a preclinical and translational research organisation supporting oncology, CNS, and radiopharmaceutical development, announced on Friday that it has formed a strategic partnership with CDMO Nucleus RadioPharma Inc to help radiopharmaceutical developers move more efficiently from early target validation through clinical manufacturing.

Under the agreement each company will refer qualified customer opportunities to one another, supported by a joint governance structure and a shared commitment to reducing the time, cost, and friction that programmes typically encounter at the handoff between preclinical imaging and GMP manufacturing.

For Perceptive Discovery, this partnership extends its preclinical imaging services into a defined pathway toward clinical-scale radiopharmaceutical production. Imaging-derived biodistribution and dosimetry data are central to radioligand candidate selection and to the design of first-in-human studies, and a coordinated transition into GMP manufacturing helps preserve that scientific continuity as programmes advance, the company said.